30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

AN2 Therapeutics Inc (ANTX)

Track

Over the last 90 days, AN2 Therapeutics Inc. has seen a net sell-off of $1,173.95 from insiders, with one transaction recorded. This activity is primarily driven by executive sales. The stock has experienced a 22.5% price increase over the past 90 days. No recent earnings reports with beat/miss data are available.
Stock chart
Ticker: ANTX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Williams Sarah Joanne
Principal Accounting Officer
1 sale — total 100,000 USD
Sale 29 May 2026
Value US$1,754,693.52 | Price 163.23 | Shares 48,946
Sale 3 Mar 2026
Value US$494,409.92 | Price 449.00 | Shares 22,765
Sale 6 Jan 2026
Value US$2,892.30 | Price 1.01 | Shares 2,858
Planned sale 6 Jan 2026
Value US$6,027.47 | Price 1.01 | Shares 5,956
Sale 6 Jan 2026
Value US$7,014.17 | Price 1.01 | Shares 6,931
Planned sale 6 Jan 2026
Value US$5,578.14 | Price 1.01 | Shares 5,512
Sale 5 Jan 2026
Value US$3,614.81 | Price 1.00 | Shares 3,604
Planned sale 5 Jan 2026
Value US$3,304.88 | Price 1.00 | Shares 3,295
Sale 5 Jan 2026
Value US$17,948.09 | Price 1.00 | Shares 17,923
Planned sale 5 Jan 2026
Value US$3,304.88 | Price 1.00 | Shares 3,295
Planned sale 4 Nov 2025
Value US$872.10 | Price 1.14 | Shares 765
Planned sale 4 Nov 2025
Value US$3,213.66 | Price 1.14 | Shares 2,819
Buy 2 Jun 2025
Value US$10,665.00 | Price 1.07 | Shares 10,000
Sale 30 May 2025
Value US$7,226.80 | Price 1.03 | Shares 7,000
Sale 30 May 2025
Value US$429,250.00 | Price 1.01 | Shares 425,000
Sale 28 May 2025
Value US$218,000.00 | Price 1.09 | Shares 200,000
Sale 28 May 2025
Value US$116,000.00 | Price 1.16 | Shares 100,000
Sale 28 May 2025
Value US$2,320,000.00 | Price 1.16 | Shares 2,000,000
Buy 28 May 2025
Value US$10,133.11 | Price 1.18 | Shares 8,610
Planned sale 3 Jan 2025
Value US$3,965.34 | Price 1.34 | Shares 2,957
Planned sale 3 Jan 2025
Value US$3,965.34 | Price 1.34 | Shares 2,957
Sale 3 Jan 2025
Value US$2,720.89 | Price 1.34 | Shares 2,029
Sale 3 Jan 2025
Value US$12,958.08 | Price 1.34 | Shares 9,663
Buy 10 Dec 2024
Value US$7,467.50 | Price 1.49 | Shares 5,000
Buy 10 Dec 2024
Value US$7,462.00 | Price 1.49 | Shares 5,000
Buy 9 Dec 2024
Value US$26,406.66 | Price 1.43 | Shares 18,483
Buy 9 Dec 2024
Value US$17,576.96 | Price 1.43 | Shares 12,289
Buy 6 Dec 2024
Value US$9,427.49 | Price 1.45 | Shares 6,517
Buy 6 Dec 2024
Value US$18,367.40 | Price 1.45 | Shares 12,711
Buy 27 Nov 2024
Value US$35,417.50 | Price 1.42 | Shares 25,000
Buy 27 Nov 2024
Value US$35,422.50 | Price 1.42 | Shares 25,000
Buy 27 Nov 2024
Value US$2,800.00 | Price 1.40 | Shares 2,000
Buy 26 Nov 2024
Value US$17,427.50 | Price 1.39 | Shares 12,500
Buy 26 Nov 2024
Value US$17,417.50 | Price 1.39 | Shares 12,500
Buy 20 Nov 2024
Value US$28,870.00 | Price 1.15 | Shares 25,000
Buy 20 Nov 2024
Value US$29,000.00 | Price 1.16 | Shares 25,000
Buy 19 Nov 2024
Value US$77,730.00 | Price 1.04 | Shares 75,000
Buy 19 Nov 2024
Value US$77,527.50 | Price 1.03 | Shares 75,000
Buy 19 Nov 2024
Value US$5,050.00 | Price 1.01 | Shares 5,000
Buy 18 Nov 2024
Value US$19,996.00 | Price 1.00 | Shares 20,000
Buy 18 Nov 2024
Value US$49,970.00 | Price 1.00 | Shares 50,000
Proposed sale 15 Aug 2024
Value US$1,699,999.00 | Price 1.00 | Shares 1,699,998
Proposed sale 15 Aug 2024
Value US$305,998.00 | Price 1.02 | Shares 299,999
Buy 14 Aug 2024
Value US$1,560,000.00 | Price 1.04 | Shares 1,500,000
Sale 9 Aug 2024
Value US$123,939.72 | Price 1.08 | Shares 114,759
Sale 9 Aug 2024
Value US$3,683,161.80 | Price 1.08 | Shares 3,410,335
Sale 18 Jan 2024
Value US$1,911,410.00 | Price 19.11 | Shares 100,000
Proposed sale 18 Jan 2024
Value US$1,911,410.00 | Price 19.11 | Shares 100,000
Sale 16 Jan 2024
Value US$312,572.55 | Price 19.65 | Shares 15,907
Sale 16 Jan 2024
Value US$1,652,427.45 | Price 19.65 | Shares 84,093
Sale 16 Jan 2024
Value US$312,572.55 | Price 19.65 | Shares 15,907
Sale 16 Jan 2024
Value US$1,652,427.45 | Price 19.65 | Shares 84,093
Proposed sale 16 Jan 2024
Value US$1,755,861.84 | Price 20.88 | Shares 84,093
Proposed sale 16 Jan 2024
Value US$332,138.00 | Price 20.88 | Shares 15,907
Planned sale 12 Jan 2024
Value US$15,753.29 | Price 21.91 | Shares 719
Planned sale 12 Jan 2024
Value US$15,475.52 | Price 21.92 | Shares 706
Planned sale 10 Jan 2024
Value US$39,456.00 | Price 21.92 | Shares 1,800
Planned sale 10 Jan 2024
Value US$40,987.17 | Price 21.93 | Shares 1,869
Proposed sale 10 Jan 2024
Value US$203,307.79 | Price 21.53 | Shares 9,443
Proposed sale 10 Jan 2024
Value US$237,540.49 | Price 21.53 | Shares 11,033
Planned sale 9 Jan 2024
Value US$149,367.25 | Price 20.14 | Shares 7,417
Planned sale 2 Jan 2024
Value US$51,967.12 | Price 20.12 | Shares 2,583
Planned sale 2 Jan 2024
Value US$55,802.43 | Price 20.09 | Shares 2,777
Proposed sale 2 Jan 2024
Value US$56,900.73 | Price 20.49 | Shares 2,777
Proposed sale 2 Jan 2024
Value US$204,900.00 | Price 20.49 | Shares 10,000
Planned sale 14 Nov 2023
Value US$4,650.05 | Price 16.15 | Shares 288
Planned sale 14 Nov 2023
Value US$24,574.21 | Price 16.15 | Shares 1,522
Planned sale 14 Nov 2023
Value US$4,650.05 | Price 16.15 | Shares 288
Planned sale 14 Nov 2023
Value US$24,574.21 | Price 16.15 | Shares 1,522
Proposed sale 14 Nov 2023
Value US$27,131.90 | Price 14.99 | Shares 1,810
Planned sale 2 Oct 2023
Value US$14,495.14 | Price 16.07 | Shares 902
Planned sale 2 Oct 2023
Value US$76,653.90 | Price 16.07 | Shares 4,770
Planned sale 2 Oct 2023
Value US$14,495.14 | Price 16.07 | Shares 902
Planned sale 2 Oct 2023
Value US$76,653.90 | Price 16.07 | Shares 4,770
Proposed sale 2 Oct 2023
Value US$91,205.76 | Price 16.08 | Shares 5,672
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-02 2026-05-29 S Sale
Williams Sarah Joanne

Principal Accounting Officer

Officer
48,946 -8.7%
163.23
US$1,754,694 		48,946 -8.7% 163.23 US$1,754,694
2026-03-05 2026-03-03 S Sale
Williams Sarah Joanne

Principal Accounting Officer

Officer
22,765 +31.4%
449.00
US$494,410 		22,765 +31.4% 449.00 US$494,410
2026-01-07 2026-01-06 S Sale
1.7
Prior Stephen David

Chief Strategy Officer

Officer
36,315 +47.5%
470.54
US$2,086,550 		36,315 +47.5% 470.54 US$2,086,550
2026-01-07 2026-01-06 PlS Planned sale
Chanda Sanjay

Chief Development Officer

Officer
5,956 -7.3%
1.01
US$6,027 		5,956 -7.3% 1.01 US$6,027
2026-01-07 2026-01-06 S Sale
1.7
Eizen Joshua M

See Remarks

Officer
6,931 -4.3%
1.01
US$7,014 		6,931 -4.3% 1.01 US$7,014
2026-01-07 2026-01-06 PlS Planned sale
Day Lucy

Chief Financial Officer

Officer
5,512 -6.8%
1.01
US$5,578 		5,512 -6.8% 1.01 US$5,578
2026-01-07 2026-01-05 S Sale
1.7
Prior Stephen David

Chief Strategy Officer

Officer
3,604 -5.5%
1.00
US$3,615 		3,604 -5.5% 1.00 US$3,615
2026-01-07 2026-01-05 PlS Planned sale
Chanda Sanjay

Chief Development Officer

Officer
3,295 -3.9%
1.00
US$3,305 		3,295 -3.9% 1.00 US$3,305
2026-01-07 2026-01-05 S Sale
1.7
Eizen Joshua M

See Remarks

Officer
17,923 -10.1%
1.00
US$17,948 		17,923 -10.1% 1.00 US$17,948
2026-01-07 2026-01-05 PlS Planned sale
Day Lucy

Chief Financial Officer

Officer
3,295 -3.9%
1.00
US$3,305 		3,295 -3.9% 1.00 US$3,305
2025-11-06 2025-11-04 PlS Planned sale
1.7
Prior Stephen David

Chief Strategy Officer

Officer
765 -1.2%
1.14
US$872 		765 -1.2% 1.14 US$872
2025-11-06 2025-11-04 PlS Planned sale
1.7
Eizen Joshua M

See Remarks

Officer
2,819 -1.6%
1.14
US$3,214 		2,819 -1.6% 1.14 US$3,214
2025-06-03 2025-06-02 B Purchase
4.1
Easom Eric

Chief Executive Officer

Executive Director
10,000 +4.1%
1.07
US$10,665 		10,000 +4.1% 1.07 US$10,665
2025-05-30 2025-05-30 S Sale
2.9
Leonard Braden Michael
Large shareholder
7,000 -0.2%
1.03
US$7,227 		7,000 -0.2% 1.03 US$7,227
2025-05-30 2025-05-30 S Sale
2.9
Leonard Braden Michael
Large shareholder
425,000 -11.6%
1.01
US$429,250 		425,000 -11.6% 1.01 US$429,250
2025-06-16 2025-05-28 S Sale
2.9
Leonard Braden Michael
Large shareholder
200,000 -6.2%
1.09
US$218,000 		200,000 -6.2% 1.09 US$218,000
2025-05-30 2025-05-28 S Sale
2.9
Leonard Braden Michael
Large shareholder
100,000 -2.7%
1.16
US$116,000 		100,000 -2.7% 1.16 US$116,000
2025-05-30 2025-05-28 S Sale
2.9
Leonard Braden Michael
Large shareholder
2,000,000 -34.8%
1.16
US$2,320,000 		2,000,000 -34.8% 1.16 US$2,320,000
2025-05-29 2025-05-28 B Purchase
1.5
FitzPatrick Margaret M
Non-Executive Director
8,610 +inf%
1.18
US$10,133 		8,610 +inf% 1.18 US$10,133
2025-01-07 2025-01-03 PlS Planned sale
Day Lucy

Chief Financial Officer

Officer
2,957 -8.3%
1.34
US$3,965 		2,957 -8.3% 1.34 US$3,965
2025-01-07 2025-01-03 PlS Planned sale
Chanda Sanjay

Chief Development Officer

Officer
2,957 -9.0%
1.34
US$3,965 		2,957 -9.0% 1.34 US$3,965
2025-01-07 2025-01-03 S Sale
1.7
Prior Stephen David

Chief Strategy Officer

Officer
2,029 -5.7%
1.34
US$2,721 		2,029 -5.7% 1.34 US$2,721
2025-01-07 2025-01-03 S Sale
1.7
Eizen Joshua M

See Remarks

Officer
9,663 -7.6%
1.34
US$12,958 		9,663 -7.6% 1.34 US$12,958
2024-12-10 2024-12-10 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
5,000 +0.8%
1.49
US$7,468 		5,000 +0.8% 1.49 US$7,468
2024-12-10 2024-12-10 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
5,000 +0.9%
1.49
US$7,462 		5,000 +0.9% 1.49 US$7,462
2024-12-10 2024-12-09 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
18,483 +2.9%
1.43
US$26,407 		18,483 +2.9% 1.43 US$26,407
2024-12-10 2024-12-09 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
12,289 +2.2%
1.43
US$17,577 		12,289 +2.2% 1.43 US$17,577
2024-12-10 2024-12-06 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
6,517 +1.0%
1.45
US$9,427 		6,517 +1.0% 1.45 US$9,427
2024-12-10 2024-12-06 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
12,711 +2.3%
1.45
US$18,367 		12,711 +2.3% 1.45 US$18,367
2024-11-27 2024-11-27 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
25,000 +4.2%
1.42
US$35,418 		25,000 +4.2% 1.42 US$35,418
2024-11-27 2024-11-27 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
25,000 +4.7%
1.42
US$35,422 		25,000 +4.7% 1.42 US$35,422
2024-11-27 2024-11-27 B Purchase
4.3
Zakrzewski Joseph S
Non-Executive Director
2,000 +1.6%
1.40
US$2,800 		2,000 +1.6% 1.40 US$2,800
2024-11-27 2024-11-26 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
12,500 +2.1%
1.39
US$17,428 		12,500 +2.1% 1.39 US$17,428
2024-11-27 2024-11-26 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
12,500 +2.4%
1.39
US$17,418 		12,500 +2.4% 1.39 US$17,418
2024-11-21 2024-11-20 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
25,000 +5.1%
1.15
US$28,870 		25,000 +5.1% 1.15 US$28,870
2024-11-21 2024-11-20 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
25,000 +4.5%
1.16
US$29,000 		25,000 +4.5% 1.16 US$29,000
2024-11-21 2024-11-19 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
75,000 +18.1%
1.04
US$77,730 		75,000 +18.1% 1.04 US$77,730
2024-11-21 2024-11-19 B Purchase
2.7
Readnour Robin Shane
Non-Executive Director
75,000 +15.5%
1.03
US$77,528 		75,000 +15.5% 1.03 US$77,528
2024-11-20 2024-11-19 B Purchase
4.3
Zakrzewski Joseph S
Non-Executive Director
5,000 +4.2%
1.01
US$5,050 		5,000 +4.2% 1.01 US$5,050
2024-11-20 2024-11-18 B Purchase
4.3
Zakrzewski Joseph S
Non-Executive Director
20,000 +20.4%
1.00
US$19,996 		20,000 +20.4% 1.00 US$19,996
2024-11-18 2024-11-18 B Purchase
4.1
Easom Eric

Chief Executive Officer

Executive Director
50,000 +4.9%
1.00
US$49,970 		50,000 +4.9% 1.00 US$49,970
2024-08-15 2024-08-15 PrS Proposed sale
RA Capital Healthcare Fund LP

Affiliate
1,699,998
1.00
US$1,699,999 		1,699,998 1.00 US$1,699,999
2024-08-15 2024-08-15 PrS Proposed sale
RA Capital Nexus Fund II, L.P.

Affiliate
299,999
1.02
US$305,998 		299,999 1.02 US$305,998
2024-08-14 2024-08-14 B Purchase
2.9
Leonard Braden Michael
Large shareholder
1,500,000 +35.3%
1.04
US$1,560,000 		1,500,000 +35.3% 1.04 US$1,560,000
2024-08-13 2024-08-09 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
114,759 -27.6%
1.08
US$123,940 		114,759 -27.6% 1.08 US$123,940
2024-08-13 2024-08-09 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
3,410,335 -66.4%
1.08
US$3,683,162 		3,410,335 -66.4% 1.08 US$3,683,162
2024-01-19 2024-01-18 S Sale
4.3
Zakrzewski Joseph S
Non-Executive Director
100,000 -19.8%
19.11
US$1,911,410 		100,000 -19.8% 19.11 US$1,911,410
2024-01-18 2024-01-18 PrS Proposed sale
4.3
Z3 TRUST

Director

Non-Executive Director
100,000
19.11
US$1,911,410 		100,000 19.11 US$1,911,410
2024-01-18 2024-01-16 S Sale
3.7
Aziz Kabeer
Non-Executive Director
15,907 -4.0%
19.65
US$312,573 		15,907 -4.0% 19.65 US$312,573
2024-01-18 2024-01-16 S Sale
3.7
Aziz Kabeer
Non-Executive Director
84,093 -4.0%
19.65
US$1,652,427 		84,093 -4.0% 19.65 US$1,652,427
2024-01-18 2024-01-16 S Sale
3.7
Adjuvant Global Health Technology Fund, L.P.
Large shareholder
15,907 -4.0%
19.65
US$312,573 		15,907 -4.0% 19.65 US$312,573
2024-01-18 2024-01-16 S Sale
3.7
Adjuvant Global Health Technology Fund, L.P.
Large shareholder
84,093 -4.0%
19.65
US$1,652,427 		84,093 -4.0% 19.65 US$1,652,427
2024-01-16 2024-01-16 PrS Proposed sale
Adjuvant Global Health Technology Fund DE, L.P.

Shareholder
15,907
20.88
US$332,138 		15,907 20.88 US$332,138
2024-01-16 2024-01-16 PrS Proposed sale
3.7
Adjuvant Global Health Technology Fund, L.P.

Shareholder
84,093
20.88
US$1,755,862 		84,093 20.88 US$1,755,862
2024-01-17 2024-01-12 PlS Planned sale
2.7
Readnour Robin Shane
Non-Executive Director
719 -0.1%
21.91
US$15,753 		719 -0.1% 21.91 US$15,753
2024-01-17 2024-01-12 PlS Planned sale
2.7
Readnour Robin Shane
Non-Executive Director
706 -0.2%
21.92
US$15,476 		706 -0.2% 21.92 US$15,476
2024-01-12 2024-01-10 PlS Planned sale
2.7
Readnour Robin Shane
Non-Executive Director
1,800 -0.4%
21.92
US$39,456 		1,800 -0.4% 21.92 US$39,456
2024-01-12 2024-01-10 PlS Planned sale
2.7
Readnour Robin Shane
Non-Executive Director
1,869 -0.4%
21.93
US$40,987 		1,869 -0.4% 21.93 US$40,987
2024-01-10 2024-01-10 PrS Proposed sale
MGC VENTURE PARTNERS 2018 ,LP

Officer

Officer
9,443
21.53
US$203,308 		9,443 21.53 US$203,308
2024-01-10 2024-01-10 PrS Proposed sale
MGC VENTURE PARTNERS QP 2018 ,LP

Officer

Officer
11,033
21.53
US$237,540 		11,033 21.53 US$237,540
2024-01-11 2024-01-09 PlS Planned sale
Krause Kevin Michael

Chief Strategy Officer

Officer
7,417 -79.5%
20.14
US$149,367 		7,417 -79.5% 20.14 US$149,367
2024-01-04 2024-01-02 PlS Planned sale
Krause Kevin Michael

Chief Strategy Officer

Officer
2,583 -57.4%
20.12
US$51,967 		2,583 -57.4% 20.12 US$51,967
2024-01-04 2024-01-02 PlS Planned sale
4.1
Easom Eric

Chief Executive Officer

Executive Director
2,777 -56.6%
20.09
US$55,802 		2,777 -56.6% 20.09 US$55,802
2024-01-02 2024-01-02 PrS Proposed sale
4.1
ERIC EASOM

Officer

Officer
2,777
20.49
US$56,901 		2,777 20.49 US$56,901
2024-01-02 2024-01-02 PrS Proposed sale
KEVIN KRAUSE

Officer

Officer
10,000
20.49
US$204,900 		10,000 20.49 US$204,900
2023-11-16 2023-11-14 PlS Planned sale
3.7
Aziz Kabeer
Non-Executive Director Large shareholder
288 -0.1%
16.15
US$4,650 		288 -0.1% 16.15 US$4,650
2023-11-16 2023-11-14 PlS Planned sale
3.7
Aziz Kabeer
Non-Executive Director Large shareholder
1,522 -0.1%
16.15
US$24,574 		1,522 -0.1% 16.15 US$24,574
2023-11-16 2023-11-14 PlS Planned sale
3.7
Adjuvant Global Health Technology Fund, L.P.
Large shareholder
288 -0.1%
16.15
US$4,650 		288 -0.1% 16.15 US$4,650
2023-11-16 2023-11-14 PlS Planned sale
3.7
Adjuvant Global Health Technology Fund, L.P.
Large shareholder
1,522 -0.1%
16.15
US$24,574 		1,522 -0.1% 16.15 US$24,574
2023-11-14 2023-11-14 PrS Proposed sale
ADJUVANT CAPITAL GP, L.P.

Officer

Officer
1,810
14.99
US$27,132 		1,810 14.99 US$27,132
2023-10-03 2023-10-02 PlS Planned sale
3.7
Adjuvant Global Health Technology Fund, L.P.
Large shareholder
902 -0.2%
16.07
US$14,495 		902 -0.2% 16.07 US$14,495
2023-10-03 2023-10-02 PlS Planned sale
3.7
Adjuvant Global Health Technology Fund, L.P.
Large shareholder
4,770 -0.2%
16.07
US$76,654 		4,770 -0.2% 16.07 US$76,654
2023-10-03 2023-10-02 PlS Planned sale
3.7
Aziz Kabeer
Non-Executive Director Large shareholder
902 -0.2%
16.07
US$14,495 		902 -0.2% 16.07 US$14,495
2023-10-03 2023-10-02 PlS Planned sale
3.7
Aziz Kabeer
Non-Executive Director Large shareholder
4,770 -0.2%
16.07
US$76,654 		4,770 -0.2% 16.07 US$76,654
2023-10-02 2023-10-02 PrS Proposed sale
ADJUVANT CAPITAL GP, L.P.

Officer

Officer
5,672
16.08
US$91,206 		5,672 16.08 US$91,206
Explore more

More insider trading research around AN2 Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America